Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
View: Text | PDF
Research Article Cell biology Oncology

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models

  • Text
  • PDF
Abstract

T follicular helper (TFH) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling TFH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of TFH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13hi TFH cells, and its deficiency impaired TFH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key TFH-associated loci, including Cxcr5 and Il6ra. Notably, ginkgolic acid treatment suppressed TFH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during TFH differentiation and suggest that modulation of this pathway may provide a strategy to tune TFH-driven immune responses.

Authors

Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li

×

Figure 1

METTL8 is expressed in CXCL13hi CD4+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
METTL8 is expressed in CXCL13hi CD4+ T cells.
(A) Spatial expression of ...
(A) Spatial expression of CD4, CXCL13, and PDCD1 in skin lesions from patients with anti–PD-1 treated tumors. (B) Schematic diagram of mouse model: B16F10 cells were subcutaneously injected into B6 mice and intraperitoneally injected with anti–PD-1 or IgG every 2 days from days 8 to 12, then analyzed at day 14. (C) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (gated on CD44hiCD62Llo CD4+ T cells) in the TdLNs of non-tumor, IgG‑, or anti–PD‑1–treated tumor mice (n = 5/group). (D) Frequency and absolute number of CXCL13hi cells (gated on BCL6+CXCR5+ GC TFH cells) in TdLNs of B16F10 tumor–bearing mice treated with IgG or anti–PD‑1 (n = 8–9/group). (E) MFI of CXCL13 in BCL6+CXCR5+ TFH cells in the TdLNs of B16F10 tumor–bearing mice treated with IgG or anti–PD‑1 (n = 7/group). (F) Mettl8-tdTomato-Flag mice were infected with LCMV-Armstrong and analyzed at 8 dpi. Splenic CD44hiCD62Llo CD4+ cells were gated; CXCL13 expression is shown for PD-1hiCXCR5hi GC TFH, PD-1loCXCR5+ TFH, and CXCR5− non-TFH subsets (n = 3/group). (G) Bubble plot of selected TFH/TH1-related differentially expressed genes between CXCL13hi and CXCL13lo clusters. (H) Heatmap of top 50 differentially expressed genes between CD4+ T cells from patients with SS versus healthy controls (scRNA-seq). (I) Cross-comparison of gene expression changes in CD4+ T cells from patients with disease versus healthy controls and in TFH versus TH1 cells. Selected genes shared between the 2 comparisons are highlighted. Mouse data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 1-way ANOVA (C and F) and 2-tailed Student’s t test (D and E). *P < 0.05; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts